News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 294014

Thursday, 08/31/2017 8:18:43 PM

Thursday, August 31, 2017 8:18:43 PM

Post# of 347009

..propietary CSF1R inhibitor program"



Now I say Peregrine was involved with CSF1R inhibitor program and was nondisclosed ...

....Eli Lilly digging deeper into CSF1R and Peregrine must unveil a bit of their non disclosed collaborations


Colony-stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), is a cell-surface receptor for its ligands, colony-stimulating factor 1 (CSF1) and IL-34.1,2 CSF1R plays an important role as regulator of the development, morphology, survival, and functions of tissue macrophages as well as tumor-associated macrophages (TAMs). CSF1 is involved in the recruitment and survival of macrophages in tumors. Increased CSF1 expression is implicated in tumor progression and metastasis, and is associated with poor prognosis in some cancers.3
Molecule

LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R, preventing ligands CSF1 and IL-342 from binding to the receptor and inhibiting TAMs from receiving CSF1 signals, decreasing their survival and relieving the effect of TAMs in the tumor.4

Clinical Development

LY3022855 (IMC-CS4) is being investigated in phase I clinical trials, including a collaboration clinical trial with another immuno-oncology agent.

http://www.lillyoncologypipeline.com/molecule/csf-1-r-antibody/overview
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y